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ing to attitudes and beliefs relevant to the therapy area. Results: Quantitative 
segmentation identified key distinct segments of payers displaying unique atti-
tudes and beliefs towards entry of the novel class of anticoagulation agents. The 
segmentation approach identified key differentiating factors between segments, 
allowing full profiling of each group. Payers’ underlying values were explored 
with a view to gain insight to what is important to them as individuals as well as 
decision makers, what motivates them and what restricts them. ConClusions: 
Findings from this research were utilized to prioritise targeting of payer segments. 
In addition, communication and messaging strategies were optimised for these 
payer groups. Subsequently a post-project feedback workshop with the pharma-
ceutical client was conducted. The poster will discuss how the research was used 
by the pharmaceutical client and the benefits of this strategic tool to the brand 
team.
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objeCtives: To assess whether the prescribing pattern of statins changed after 
reimbursement criteria revision and regional policies in a general practice in 
southern Italy. Methods: Analysis has been performed on a database of 123 
medical practitioners that have managed an average of 190.000 inhabitants in 
the Campania Region (south of Italy). Prevalence of use and incidence of new 
treatments were calculated from Jan 2012 to Jun 2013. Statin users were stratified 
into three groups (Moderate Cardiovascular Risk, MR; High Cardiovascular Risk, 
HR; Very High Cardiovascular Risk, VHR) according to new criteria for reimburse-
ment for lipid lowering agents revised by the Italian Drug Agency (AIFA) (Nota 13).  
Results: After the reimbursement criteria revision (November 2012), the prev-
alence of statin use slightly decreased reaching 6.6% in the second quarter of 
2013 (-14% compared to second quarter of 2012). Stratified by level of CV risk, the 
prevalence of statin use is reduced by 24.9% into MR, 13.1% into HR and 5.9% into 
VHR, while incidence of new users of 22.4%, 34 5% and 45.8% respectively. In the 
second quarter of 2013, atorvastatin (+45.3%) was prescribed in 57,5% of patients 
in MR group (+45.3%), rosuvastatin 5.9% with (-60.1%) and 1.6% with simvasta-
tin + ezetimide (-57.5%); in HR group, 40.7% (+20.8) atorvastatin, 5.3% (-57.0%) 
rosuvastatin and 2.1% (- 42.3%) simvastatin + ezetimide; in VHR, 56.3% (+15.8) 
atorvastatin, 12.5% (-37.5%) rosuvastatin and 2.1% (-27.1%) simvastatin + ezetim-
ide. ConClusions: The revision of reimbursement criteria and the regional poli-
cies led to significant changes in general practice in southern Italy resulting in a 
reduction in the statin use, especially in patients who could potentially benefit 
from it most. The results of the study provide useful information for the general 
practitioner about areas for improvement prescriptive.
PCV149
assessment Of the ImPaCt Of LegIsLatIOn On the utILIzatIOn Of 
statIns In sLOVakIa
Minariková D.1, Malovecká I.1, Foltan V.2, Lehocká L.1
1Comenius University, Bratislava, Slovak Republic, 2Faculty of Pharmacy, Comenius University, 
Bratislava, Slovak Republic
objeCtives: Frequent legislative changes that have brought the Slovak health care 
reform over the past decade, reflected also on drug policy and especially on the 
prices of medicines and total consumption of medicines. Generic substitution was 
introduced to save both health insurance and patient’s finances. Methods: Data 
on prices and consumption of lipid-lowering agent medicines were collected from 
Slovak Ministry of Health and Health insurance. Data processing, we used a uniform 
methodology recommended by the WHO - ATC / DDD classification and basic statisti-
cal methods of observing. In case of national data, we reported consumption in units 
of DDD per 1,000 inhabitants for one day (DID). Results: A class of lipid-lowering 
agent medicines (C10A) poses in recent years on Slovak market expanding group. Its 
number significantly increased in direct proportion with the introduction of generic 
drugs, mainly after 2004, when generic substitution was enacted and later after 
2011, when mandatory generic prescribing entry into the force. The proportion of 
total medicines and generic drugs in the group C10A were x2008total-medicines/%generic-
drugs= 55/74,6 types and x2014total-medicines/%generic-drugs= 203/94 types. The number of 
generic drugs with atorvastatin ranged x2008-2014= 4-18, rosuvastatin x2008-2014= 3-11, 
simvastatin x2008-2014= 7-7, fluvastatin x2008-2014= 1-1, lovastatin x2008-2014= 1-5. The 
consumption of medicines with atorvastatin x2008-2014-packages= +Δ 47,7%, x2008-2014-
value= +Δ 20,1% € , rosuvastatin x2008-2014-packages= +Δ 18,8%, x2008-2014-value= -Δ 77,4 % € , 
simvastatin x2008-2014-packages= -Δ 48,6%, x2008-2014-value= -Δ 79,6 % € , fluvastatin x2008-
2014-packages= -Δ 50,5%, x2008-2014-value= -Δ 90,4 % € , lovastatin x2008-2014-packages= -Δ 70,1%, 
x2008-2014-value= -Δ 81,8 % € . In the years 2008-2013 consumption of C10A in Slovakia 
increased by 77,5 per DDD/1000 inh. /day (DID). OECD statistics from 2011 indicate 
consumption of lipid-lowering agents amounting to 130 DID, while at the end of 
2013 according to our data analysis increased to 142.8 DID. ConClusions: Overall 
changes in legislation of drug policy brought rising utilization of lipid-lowering agent 
medicines and in 2011 Slovakia together with Great Britain was on the second place 
with 130 DID consumption of lipid-lowering agents.
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following with 15% of the rest patients switching to rivaroxaban per year. Then the 
model estimates the number of DVT, pulmonary embolism (PE), intracranial bleeds 
(ICH) and major extracranial bleeds (ECH) per year. Results: The new DVT patients 
are 287,813 per year. For those patients, with 20% patients switching to rivaroxa-
ban from LMWH+VKA in the first year, the recurrent venous thrombus embolism 
(VTE) events, including DVT and PE, reduced 4.6%, major bleeding events including 
ECH and ICH reduced 7% with 1% minor bleeding increasing. To the third year, the 
recurrent VTE events reduced 11.4%, major bleeding events reduced 17% with 2% 
minor bleeding increasing compared with the current situation. ConClusions: 
Rivaroxaban may decrease the clinical burden of DVT in China by reducing the 
incidence of recurrent VTE and fatal bleeding events. Decision-makers can find the 
exact value of rivaroxaban easily by the simple tool in different situations.
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objeCtives: Disease management programs (DMPs) for cardiovascular risk (CVR) 
and chronic obstructive pulmonary disease (COPD) are increasingly implemented 
in the Netherlands to improve quality of care and patient’s lifestyle. The aim of 
the study was to provide evidence about the (cost-) effectiveness of Dutch DMPs 
as implemented in daily practice. Methods: We compared the 2-year costs 
and changes in physical activity, smoking behaviour, and utilities between the 
most and the least comprehensive DMP in four disease categories: primary CVR-
prevention, secondary CVR-prevention, both types of CVR-prevention, and COPD 
(total n: 1034). Propensity score matching increased comparability between DMPs. 
A cost-utility analysis was performed from the health care and societal perspective. 
Sensitivity analysis was performed to estimate the impact of DMP development and 
implementation costs on the cost-effectiveness. Results: Patients in the most 
comprehensive DMPs increased physical activity and had higher smoking cessation 
probabilities after 2 years in most disease categories. From a health care perspec-
tive, the incremental costs were positive in primary CVR-prevention (96% certainty), 
negative in secondary and both types of CVR prevention (93% and 98% certainty) and 
indifferent in COPD. The incremental QALYs were positive in all categories (certainty 
range: 64%-80%). The incremental cost-effectiveness ratio’s ranged from € -114,662 
to € 8,849. The results from the societal perspective and the sensitivity analysis were 
in the same line. ConClusions: The most comprehensive DMPs for CVR and COPD 
were cost-effective compared to the least comprehensive DMPs. The challenge for 
Dutch stakeholders is to find the optimal mixture of interventions.
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objeCtives: This study examines the extent to which Integrated Care Programs 
lead to an improvement in the quality of patient care. The aim of the study is 
to carry out a quantitative analysis of differences in quality between patients 
participating in Disease Management Programs (DMPs) and patients receiving 
regular care, regardless of health insurance status, program, or region. Methods: 
The study used data from the representative IMS Disease Analyzer database. It 
included patients with a confirmed diagnosis of hypertension who started anti-
hypertensive therapy in the period between January 2010 and December 2012. 
The primary dependent variable of the study was the change in blood pressure 
after at least six months of antihypertensive treatment. To assess this variable, we 
determined the proportion of patients with a blood pressure of below 140/90 in the 
period between day 183 and day 365 after initiation of treatment (index date). In 
order to eliminate confounding factors, we performed one-to-one matching based 
on a propensity score. Results: 1,317 patients participating in the integrated 
care program (ICP) and 1,317 patients not participating in such a program were 
available for further analyses following the propensity score matching. Patients 
in both groups were very similar with respect to demographic variables and 
antihypertensive therapy. The proportion of patients with blood pressure values 
< 140/90 after one year of treatment was 33.6% in the group of ICP participants 
and 22.7% in the group of non-ICP patients (p< 0.0001). The chance of reaching 
the treatment goal was significantly higher in the group of patients participating 
in an integrated health program (OR: 1.73; 95% CI: 1.45-2.05). ConClusions: It 
is evident that DMP participants have a significantly better chance of achieving 
the therapy goal. Thus, it can be established that integrated health care programs 
have a positive effect on quality.
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objeCtives: The research aimed to develop an attitudinal based, payer segmen-
tation approach to explore payers’ attitudes and behaviours towards the man-
aged entry of novel agents in the anticoagulation area in the health care systems 
of countries within the EU. The segmentation exercise explored payers’ drivers, 
motivations, barriers and limitations when assessing, endorsing or restricting new 
agents. Methods: Qualitative in-depth telephone interviews were conducted 
to explore payers’ views, along with perceived challenges relating to the entry of 
novel class of anticoagulation agents. Followed by a quantitative data collection 
and advanced statistical analysis methodology was employed with regional and 
local payers in each of the researched markets to define the segmentation accord-
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A499
PCV153
dabIgatran users wIth nOn-VaLVuLar atrIaL fIbrILLatIOn In the us: a 
CharaCterIzatIOn Of dabIgatran InItIatOrs and swItChers
Shash D.1, Schnee J.2, Schneider G.3, Schoof N.1, Zint K.1, Clemens A.4, Bartels D.B.1
1Boehringer Ingelheim GmbH, Ingelheim, Germany, 2Boehringer Ingelheim Pharmaceuticals, Inc, 
Ridgefield, CT, USA, 3Evidera, Lexington, MA, USA, 4University Medical Center Mainz, Mainz, 
Germany
objeCtives: In routine clinical practice the selection of a particular anticoagulant 
for treatment of a specific patient may be based on a variety of different factors. The 
aim of this study was to explore if there were differences in the characteristics of 
patients with non-valvular atrial fibrillation (NVAF) who started on dabigatran etex-
ilate (DE) and who in the prior year had no oral anticoagulant treatment (initiators) 
versus those who had previously been treated with warfarin (switchers). Methods: 
Medco claims data were used to characterize 7,055 NVAF patients from the US with 
a DE prescription between Feb 2011 and Apr 2012. The first prescription in this 
period defined the index date. The treatment-groups were stratified by initiators 
and switchers. Characteristics, comedications, and comorbidities in the 12-month-
period prior to index date were assessed. All illustrated differences were statistically 
significant (p < 0.05) (1). Results: Switchers (N = 2,585) had a mean age of 74.0 
(±9.6) years, whereas initiators (N= 1,903) were younger (mean 70.0 (±9.6) years). 
A higher proportion of switchers used comedications compared to initiators, e.g. 
beta blockers (66% vs. 59%), and gastrointestinal drugs (34% vs. 28%). Switchers 
were more likely to have congestive heart failure, hypertension, cerebrovascular 
disease, renal disease and bleeding related hospitalizations when compared to the 
initiators, and also had a higher mean CHA2DS2-VASc score (4.0 (±1.8) compared to 
initiators (3.4 (±1.9)). ConClusions: This study shows differences between patients 
who are initiating DE as first anticoagulant treatment and those who are switched 
from warfarin to DE revealing that switchers might represent a distinct patient 
population. Identifying, stratifying or accounting for such differences are necessary 
in comparisons using real world data. (1) Schoof N et al., Characteristics of patients 
with non-valvular atrial fibrillation using dabigatran or warfarin in the US. Curr 
Med Res Opin. 2013 Dec 27.
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objeCtives: In 2011, various legislative measures were adopted in Slovakia regarding 
drug policy. The aim of the submitted work is to evaluate links between the introduc-
tion of regulations and the consumption of antihypertensive drugs (AH), expendi-
tures and patient co-payments. Methods: We evaluated data on drugs consumption 
based on IMS Data. Patient co-payments data were taken from the National Health 
Information database. When evaluating the average amount of co-payments, we 
applied a weighted average, which takes into account the level of co-payment and 
consumption. Results: The consumption of AH (in DOT) increased continually in 
2006-2013 (+36%) and the turnover of AH dropped by 4% as a consequence of introduc-
ing new regulations. The impact of new regulations was expressed foremost in the 
consumption of RAS inhibitors, where the decrease in turnover after introduction of 
clusters in 2012 was 14%. In the evaluated period, the final price of AH was reduced 
by 35% (from € 8.86 to € 5.78) and the reimbursement was reduced by 52% (from € 7.87 
to € 3.76). At the same time, there was an increase in average co-payments by 105% 
(from € 0.99 to € 2.03). In the evaluated period, the patient co-payment for a fixed 
AH almost quadrupled (from € 1.05 to € 4.05). The patient paid an average of € 0.93 
more for one pack of fixed AH than for a free combination. After the introduction of 
regulations, the consumption of fixed combinations grew at a slower pace than in 
the case of monocomponents. ConClusions: The legislative changes in drug policy 
had a significant impact on the consumption of antihypertensive drugs and on the 
expense of hypertension treatment. It is necessary to monitor long-term and analyse 
the impacts of regulations on the prescription of AH and to evaluate factors that can 
influence the success of hypertension treatment.
PCV155
InItIatIOn Of OraL antICOaguLant drugs: IdentIfICatIOn Of drIVers 
Of PresCrIbIng Of new agents Versus warfarIn
Spillane S.1, Bennett K.2, Barry M.1
1HSE Medicines Management Programme, Dublin, Ireland, 2Trinity College Dublin, Dublin, Ireland
objeCtives: Oral anticoagulants (OACs), used for stroke prevention in atrial fibril-
lation, include warfarin and the newer drugs (NOACs) dabigatran, rivaroxaban and 
apixaban. High direct drug costs of the NOACs to the health care payer prompt 
monitoring of real-world NOAC uptake patterns. This study aimed to identify factors 
associated with anticoagulation initiation with NOACs versus warfarin. Methods: 
Analyses were performed using national pharmacy claims data from a means-tested 
state medical services scheme. First-time initiators of an oral anticoagulant between 
January 2009 and December 2013 with ≥ 1 year scheme eligibility and ≥ age 50 
were identified. Patients whose claims amounted to < 90 days of oral anticoagula-
tion were excluded. Patient characteristics, and number and type of concomitant 
medications at the time of first oral anticoagulant were recorded and considered 
as predictors of NOAC initiation using multivariate logistic models (odds ratios, OR 
and 95% CIs). Results: 34,944 new initiators of oral anticoagulants were included. 
In 2009, 7.6% of new initiators received a NOAC; this figure rose to 41.2% in 2013. The 
following were positively associated with NOAC initiation in multivariate analyses: 
female gender (OR: 1.14,95% CI 1.07-1.21), age < 80 (OR: 1.11, 95% CI 1.04-1.19) and 
concomitant receipt of NSAID drugs (OR: 4.04, 95% CI 3.72-4.38). Receipt of multiple 
concomitant medications was negatively associated with NOAC initiation; patients 
receiving 15+ drug classes had a 42% decreased odds of NOAC receipt (versus ≤ 5 
drug classes) (OR: 0.58, 95% CI 0.51-0.66). Specific concomitant drugs negatively 
objeCtives: Pharmaceutical expenditure accounted for between 11% to 13% of total 
health expenditure in European countries including Sweden in 2010 whereas this 
was 20% in Japan for the same year. We expect that big changes in sales pattern will 
happen as a result of patent expiry. Other changes have been seen when prescrib-
ers get negative/positive information on drugs. In this article we study the impact 
of patent expiry and negative information relating to pharmaceutical policies on 
pharmaceutical sales patterns of selected drugs in Sweden and Japan. Methods: 
we selected angiotensin-converting enzyme inhibitors (ACEs) and Angiotensin 
Ⅱantagonists (ARBs), since widely used in Sweden and Japan. Seasonal autoregres-
sive integrated moving average (ARIMA) modeling with intervention analysis was 
used to estimate the change of sales volume. Results: Losartan had a positive 
change (0.77650, p= 0.0068) in October 2010, Candesartan had a negative change 
(-0.50760, p= 0.0058) in July 2010. There were no significant differences in the sales 
volume of Losartan, Telmisartan, except for Candesartan in Japan (0.04868, p= 0.7995, 
-0.38547, p= 0.0880, and -1.21215, p= 0.001, respectively). In this study, we used a 
publication informed that Candesartan and Telmisartan had not reduced patients’ 
mortality by a journal July in 2009 as negative information. ConClusions: We 
found that the sales pattern of selected drugs were changed by negative information 
and not by the expiry of their patents in Sweden. Whereas in Japan the negative 
situation for implementing generic substitution like the therapeutic substitution 
of Trandolapril and the possibility of switching from Candesartan to a combination 
drug was seen. Further assessment will be needed since factors associated with the 
changing use of drugs will be infinite.
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objeCtives: From April 2013, the method of calculating the prescription rate 
of generic drugs in Japan was changed and protected brand name drugs were 
excluded from the denominator. In the case of Japan, which does not have a 
reference pricing system, it is thought that this will lead to a change in prescrip-
tions toward protected brand name drugs rather than drug substitution to generic 
drugs. The objective of this study is to clarify the trends in relation to the prescrip-
tion of generic drugs, through the use of administrative data on a nationwide 
level. Methods: We used survey data from dispensing pharmacies from April 
2012 to March 2014. As a comparison, we used the prescription data of 1139 acute 
care hospitals in which incentive measures for drug substitution to generic drugs 
had not taken place during the same period. The medical products in question 
were drugs for diabetes and hypotensive drugs. For data analysis used SQL Server 
2008 R2 and R. Results: As the dispensing pharmacy receives additional compen-
sation based on the rate of generic drugs dispensed by that pharmacy in the most 
recent 3 months, the dispensing rate of generic drugs will have a direct impact 
on their business. The change in the method of calculating generic drugs has a 
major impact on the dispensing pharmacies, and in this study we have shown 
the possibility of dispensing pharmacies shifting more to protected brand name 
drugs. The dispensing rate of generic drugs by acute care medical facilities has 
always been low, and thus the impact of the change in calculation of the dispens-
ing ratio is correspondingly low. ConClusions: The results of this study show 
that when encouraging drug substitution to generic drugs as a policy to reduce 
drug expenditure, it is necessary to consider measures in relation to the shift to 
protected brand name drugs.
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objeCtives: The objectives of this research are to provide an overview of the recalls 
of cardiac implant medical devices in the last decade according to the different 
categories of cardiac implant medical devices and analyze the recall reasons. On the 
basis of this analysis, this research will provide recommendations on how to build 
a high quality implant registry. Methods: A systematic search was performed 
focusing on regulatory bodies’ homepages from a range of middle and high-income 
countries with sufficient information on cardiac implant recalls and the related 
reasons. Data was extracted for the years 2004-2014 with the following criteria 
applied: cardiac implant medical device recalls and reasons for recall, i.e. harm 
or risk to patients excluding labeling or legal problems. Results: 11 countries 
have been included in the study: United States, Canada, Australia, New Zealand, 
PR China, China Hong Kong, UK, Germany, Ireland, Switzerland and Saudi Arabia. 
104 recall reports have been analyzed in total. The categories of cardiac implants 
include the following: Implantable Cardioverter Defibrillator (ICD) 40.4%; pacemaker 
14.4%; stent 14.4%; as well as Cardiac Resynchronization Therapy (CRT) 13.5%; 
leads 9.6% and replacement materials 7.7%. Referring to the recall reasons, 32.7% 
of the reports related to problems with the device battery; 30.7% of devices were 
recalled due to incorrect therapy delivery; 15.4% devices had software problems; 
15.4% devices had connection problems and 5.8% of devices did not deliver correct 
output data. ConClusions: Due to the high-risk nature of cardiac implants medi-
cal devices and their high complication rates associated with considerable associ-
ated mortality, the traceability and transparency of safety hazards information are 
crucial. By analyzing the recall information including recall reasons and cardiac 
implants categories, important information is gained that can inform a high qual-
ity cardiac implant registry for monitoring the safety of cardiac implant patients.
